XingImaging

Executive Summary

XingImaging is a Cambridge-based neuroimaging services company specializing in the efficient application of scintigraphic biomarkers for drug development and clinical research in neurodegenerative and neuropsychiatric disorders. Founded in 2018, the company leverages advanced imaging techniques to provide quantitative biomarkers that enable earlier diagnosis, patient stratification, and treatment monitoring. With the growing demand for objective endpoints in CNS clinical trials, XingImaging addresses a critical need for reliable imaging solutions that can accelerate regulatory approvals and improve therapeutic outcomes. The company's focus on scintigraphic methods, which offer high sensitivity and specificity, positions it as a potential partner for pharmaceutical companies developing therapies for Alzheimer's, Parkinson's, and other neurological conditions. Currently operating at Phase 1 stage, XingImaging is building its service infrastructure and validating its biomarker platforms. The company is likely seeking strategic collaborations and contract research opportunities to establish proof-of-concept and generate revenue. If successful, XingImaging could become a key enabler for CNS drug developers, reducing trial costs and timelines by providing robust imaging endpoints. However, as an early-stage private company, it faces challenges in scaling operations and achieving market adoption. The next 12-18 months will be critical for demonstrating clinical utility and securing partnerships that validate its technology.

Upcoming Catalysts (preview)

• H2 2026Strategic partnership with major pharma for Alzheimer's trial biomarker services50% success
• Q4 2026Publication of validation data in a peer-reviewed journal60% success
• Q3 2026ISO 15189 accreditation for clinical laboratory services70% success